Literature DB >> 8359625

The role of Helicobacter pylori in peptic ulcer disease.

M Asaka1, M Kato, M Kudo, T Meguro, T Kimura, T Miyazaki, K Inoue.   

Abstract

The linking of relapse of duodenal as well as gastric ulcers with Helicobacter pylori (H. pylori) has been a considerable advance in managing patients with peptic ulcer disease. However, pathogenetic role of H. pylori in peptic ulcer still remains unclear. The aim of this study was to assess the relationship between H. pylori infection and inflammatory cell infiltration in gastric mucosa in peptic ulcer disease. Sixty-four patients with endoscopically proven gastric ulcer and 26 patients with duodenal ulcer were evaluated by prospective study. Biopsy specimens were taken from the ulcer margin, corpus and antrum. Eradication of H. pylori was attempted by concomitant administration of amoxycillin 500 mg, metronidazole 250 mg and bismuth subnitrate 1 g twice daily for 2 weeks. H. pylori positive rates in clinical stages of gastric and duodenal ulcer showed almost the same values of more than 90%. The prevalence of H. pylori at the antrum and corpus was almost the same as that between gastric and duodenal ulcer patients, whereas a dramatic difference in the positive rates at the ulcer margin was observed between gastric and duodenal ulcer patients (83.9% and 35.0%, respectively). The prevalence of polymorphonuclear (PMN) cell infiltration at the ulcer margin was still high even at the scarring stage of gastric and duodenal ulcer with positive H. pylori, whereas a dramatic decrease of PMN cell infiltration was observed at the ulcer margin after successful eradication of H. pylori. These results suggest that H. pylori may play an important role in the pathogenesis of gastric and duodenal ulcer by inducing inflammatory cells such as PMN cells in gastric mocosa.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8359625     DOI: 10.1007/bf02989228

Source DB:  PubMed          Journal:  Gastroenterol Jpn        ISSN: 0435-1339


  6 in total

1.  Rabeprazole in treatment of acid peptic diseases: results of three placebo-controlled dose-response clinical trials in duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease (GERD). The Rabeprazole Study Group.

Authors:  M L Cloud; N Enas; T J Humphries; S Bassion
Journal:  Dig Dis Sci       Date:  1998-05       Impact factor: 3.199

2.  Hemorrhagic gastric and duodenal ulcers after the Great East Japan Earthquake Disaster.

Authors:  Kenichi Yamanaka; Hiroyuki Miyatani; Yukio Yoshida; Shinichi Asabe; Toru Yoshida; Misaki Nakano; Shin Obara; Hidehiko Endo
Journal:  World J Gastroenterol       Date:  2013-11-14       Impact factor: 5.742

3.  Does seropositivity for Helicobacter pylori antibodies increase outpatient costs for gastric and duodenal ulcer or inflammation?

Authors:  Akira Babazono; Motonobu Miyazaki; Hiroshi Une; Eiji Yamamoto; Toshihide Tsuda; Yoshio Mino; Alan L Hillman
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

4.  Analysis of Helicobacter pylori genotypes in clinical gastric wash samples.

Authors:  Shuichi Miyamoto; Yoshiyuki Watanabe; Ritsuko Oikawa; Shoko Ono; Katsuhiro Mabe; Takahiko Kudo; Hiroyuki Yamamoto; Fumio Itoh; Mototsugu Kato; Naoya Sakamoto
Journal:  Tumour Biol       Date:  2016-01-29

5.  Economic and health impacts of Helicobacter pylori eradication strategy for the treatment of peptic ulcer disease: A cost-effectiveness analysis.

Authors:  Akiko Kowada; Masahiro Asaka
Journal:  Helicobacter       Date:  2022-03-27       Impact factor: 5.182

6.  Virulent strains of Helicobacter pylori demonstrate delayed phagocytosis and stimulate homotypic phagosome fusion in macrophages.

Authors:  L A Allen; L S Schlesinger; B Kang
Journal:  J Exp Med       Date:  2000-01-03       Impact factor: 14.307

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.